The FDA approved Lytenava, for the treatment of neovascular age-related macular degeneration, according to a press release from Outlook Therapeutics.
The approval of Lytenava is marks the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.
Bevacizumab-vikg, a recombinant humanized IgG1 monoclonal antibody specific for human VEGF, binds VEGF and inhibits interactions of VEGF with Flt-1 and KDR receptors on the surface of endothelial cells.
The approved formulation of bevacizumab binds to VEGF-A and prevents interaction with VEGFR-1